HPV vaccination, are we overlooking additional opportunities to control HPV infection and transmission?

[1]  P. Szilagyi,et al.  Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices , 2019, MMWR. Morbidity and mortality weekly report.

[2]  P. van Damme,et al.  Should female sex workers be offered HPV vaccination? , 2019, Human vaccines & immunotherapeutics.

[3]  F. Parazzini,et al.  SPERANZA project: HPV vaccination after treatment for CIN2. , 2018, Gynecologic oncology.

[4]  S. Chanock,et al.  Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies , 2018, Vaccine.

[5]  P. Stern,et al.  Opportunities and challenges for human papillomavirus vaccination in cancer , 2018, Nature Reviews Cancer.

[6]  M. Bachmann,et al.  Harnessing Nanoparticles for Immunomodulation and Vaccines , 2017, Vaccines.

[7]  M. Poljak,et al.  HPV-FASTER: broadening the scope for prevention of HPV-related cancer , 2016, Nature Reviews Clinical Oncology.

[8]  C. Robertson,et al.  Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013 , 2016, Emerging infectious diseases.

[9]  C. Tanton,et al.  Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. , 2015, The Lancet. Infectious diseases.

[10]  W. Kang,et al.  Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? , 2013, Gynecologic oncology.

[11]  H. D. de Melker,et al.  Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination , 2013, Human vaccines & immunotherapeutics.

[12]  C. Wheeler,et al.  Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection , 2011, International journal of cancer.

[13]  M. Einstein,et al.  Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine , 2011, Human vaccines.

[14]  J. Schiller,et al.  A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus Infection , 2011, Journal of Virology.

[15]  D. Lowy,et al.  Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. , 2011, Journal of the National Cancer Institute.

[16]  D. Roopenian,et al.  Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection , 2011, Proceedings of the National Academy of Sciences.

[17]  M. Stanley.  HPV - immune response to infection and vaccination , 2010, Infectious Agents and Cancer.

[18]  T. Schwarz.  Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix® , 2009, Advances in therapy.

[19]  A. Schneider,et al.  Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. , 2009, Vaccine.

[20]  O. Leo,et al.  Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. , 2008, Gynecologic oncology.

[21]  A. Chaturvedi,et al.  Hematologic and biochemical changes associated with human T lymphotropic virus type 1 infection in Jamaica: a report from the population-based blood donors study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  P. Choyke,et al.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan , 2007, Nature Medicine.

[23]  D. Lowy,et al.  Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. , 2006, Vaccine.

[24]  J. Schiller,et al.  Delivering on the promise: HPV vaccines and cervical cancer , 2004, Nature Reviews Microbiology.

[25]  D. Lowy,et al.  Re: Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles , 2004 .

[26]  K. Jansen,et al.  Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. , 1997, The Journal of infectious diseases.

[27]  A. Hildesheim,et al.  Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. , 2011, The Cochrane database of systematic reviews.

[28]  D. Lowy,et al.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. , 2003, Journal of the National Cancer Institute.